Ariad (ARIA) Misses 4Q EPS Estimates, Beats on Revenue

Ariad Pharmaceuticals Inc. (ARIA) shares are up 2.18% to $7.50 in pre-market trading Thursday following the company’s fourth quarter earnings results.

The integrated global oncology firm reported EPS, excluding non-recurring items, of ($0.03) per share on revenues of $66.8 million, up 694.3% from a year ago. Analysts were expecting EPS of ($0.14) on revenues of $46.33 million.

For the year, the company reported that its loss narrowed to $162.6 million, or $0.87 per share, compared to a net loss of $274.2 million, or $1.49 per share, for the full FY 2013. Revenue in 2014 was reported as $105.4 million.

On valuation measures, Ariad Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 6.23 million shares, trade at a P/E to growth ratio of (0.17). The median Wall Street price target on the name is $8.00 with a high target of $12.00. Currently ticker boasts 6 ‘Buy’ endorsements, compared to 8 ’Holds’ and 1 ‘Sell’.

Profitability-wise, ARIA has a t-12 operating margin of (473.19%). The $1.37 billion market cap company reported $352.7 million in cash vs. $154.99 million in debt in its most recent quarter.

ARIA currently prints a one year loss of about 16.50%, and a year-to-date return of around 7%.

The chart below shows where the equity has traded over the last 52 weeks.

Ariad Pharmaceuticals Inc. is an oncology company engaged in the discovery, development, and commercialization of medicines for cancer patients. The firm was founded in 1991 and is headquartered in Cambridge, Massachusetts and Lausanne, Switzerland.

Be the first to comment

Leave a Reply

Your email address will not be published.


*